Book Appointment Now
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platform
Lilly to make a strategic investment in QurCan